[The effect of carteolol. Prolonged and increased effect by liposome suspension]

Author(s): Weber U, Michaelis L

Affiliation(s): Augenklinik des Akademischen Lehrkrankenhauses Braunschweig.

Publication date & source: 1992-12, Ophthalmologe., 89(6):449-51.

Publication type: Clinical Trial; English Abstract; Randomized Controlled Trial

Liposomes are small lipid vesicles capable of trapping beta-blockers such as carteolol within their bilayer structure, the advantage being improved drug action, prolonged action time, and a reduction in drug concentration. In a prospective, randomized double-blind trial, carteolol 2%, liposomes (frozen and thawed multilamellar vesicles, FAT-MLVs), or carteolol 2% suspended with FAT-MLVs was applied to 25 eyes of 25 patients per group in a single 20 microliters dose. Intraocular pressure was measured for 3 days. A significant reduction in the IOP was observed in the patient groups receiving carteolol and carteolol suspended with liposomes. Moreover, improved action and prolongation of drug action was noted in the carteolol/MLV group as compared to carteolol treatment alone. Hence, carteolol 2% is suitable for reduction of IOP, but a reduction of drug concentration can be achieved by suspension with liposomes, thus reducing the side effects.